UPLC-MS/MS Assay for Quantification of an Inhibitor of Kinases (Foretinib) in Plasma: Application to a Pharmacokinetic Study in Rats

Overview

Journal Saudi Pharm J

Specialty Pharmacy

Date 2020 Apr 11

PMID 32273795

Authors

Essam Ezzeldin

Muzaffar Iqbal

Yousif A Asiri

Azza A Ali

Toqa El Nahhas

Affiliations

Soon will be listed here.

Abstract

Foretinib, an oral multikinase inhibitor, is known to have anti-tumor effects against cancers. The doses and the levels of foretinib vary based on the type of cancer to be treated. An accurate and precise method is required to determine the level of foretinib and its pharmacokinetics. Here, we developed such a method, which was validated based on the guidelines of the FDA and EMA. Foretinib and ibrutinib (the internal standard (IS)) were extracted using tert-butyl methyl ether. Foretinib and IS were eluted in approximately 1.2 min. Thus, a linear, fast, accurate, and precise method was developed. The calibration curve was linear (r ˃ 0.997) in the range of 0.5-400.0 ng/mL and the lowest limit of quantitation was 0.5 ng/mL. The average recovery, accuracy, and precision were 87.9%, 88.7%, and ≤7.8%, respectively. The analyte was deemed stable using various stability tests. The validated assay was then fruitfully applied to a pharmacokinetics study in rats, which revealed that foretinib was absorbed and the maximum concentration achieved at 4.0 h after the administration of a single dose of foretinib.

References

LaChance J, Darus C, Rice L . Surgical management and postoperative treatment of endometrial carcinoma. Rev Obstet Gynecol. 2008; 1(3):97-105. PMC: 2582654. View

Leighl N, Tsao M, Liu G, Tu D, Ho C, Shepherd F . A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196. Oncotarget. 2017; 8(41):69651-69662. PMC: 5642506. DOI: 10.18632/oncotarget.18753. View

Shapiro G, McCallum S, Adams L, Sherman L, Weller S, Swann S . A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. Invest New Drugs. 2012; 31(3):742-50. DOI: 10.1007/s10637-012-9881-z. View

Camp E, Yang A, Gray M, Fan F, Hamilton S, Evans D . Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target. Cancer. 2007; 109(6):1030-9. DOI: 10.1002/cncr.22490. View

Chen H, Tsai C, Hung W . Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling. Oncotarget. 2015; 6(17):14940-52. PMC: 4558127. DOI: 10.18632/oncotarget.3613. View

Di Renzo M, Poulsom R, Olivero M, Comoglio P, Lemoine N . Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res. 1995; 55(5):1129-38. View

Attwa M, Kadi A, Darwish H, Amer S, Alrabiah H . A reliable and stable method for the determination of foretinib in human plasma by LC-MS/MS: Application to metabolic stability investigation and excretion rate. Eur J Mass Spectrom (Chichester). 2018; 24(4):344-351. DOI: 10.1177/1469066718768327. View

Smith G . European Medicines Agency guideline on bioanalytical method validation: what more is there to say?. Bioanalysis. 2012; 4(8):865-8. DOI: 10.4155/bio.12.44. View

Singh R, Patel B, Kallender H, Ottesen L, Adams L, Cox D . Population pharmacokinetics modeling and analysis of foretinib in adult patients with advanced solid tumors. J Clin Pharmacol. 2015; 55(10):1184-92. DOI: 10.1002/jcph.546. View

10.

Sharma N, Adjei A . In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs. Ther Adv Med Oncol. 2011; 3(1 Suppl):S37-50. PMC: 3225020. DOI: 10.1177/1758834011423403. View

11.

Faria C, Golbourn B, Dubuc A, Remke M, Diaz R, Agnihotri S . Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma. Cancer Res. 2014; 75(1):134-46. DOI: 10.1158/0008-5472.CAN-13-3629. View

12.

Zillhardt M, Park S, Romero I, Sawada K, Montag A, Krausz T . Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clin Cancer Res. 2011; 17(12):4042-51. PMC: 3169439. DOI: 10.1158/1078-0432.CCR-10-3387. View

13.

Kiehne K, Herzig K, Folsch U . c-met expression in pancreatic cancer and effects of hepatocyte growth factor on pancreatic cancer cell growth. Pancreas. 1997; 15(1):35-40. DOI: 10.1097/00006676-199707000-00005. View

14.

You W, Sennino B, Williamson C, Falcon B, Hashizume H, Yao L . VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 2011; 71(14):4758-68. PMC: 3138890. DOI: 10.1158/0008-5472.CAN-10-2527. View

15.

Crumbaker M, Gurney H . Dose considerations for anti-cancer drugs in metastatic prostate cancer. Prostate. 2017; 77(11):1199-1204. DOI: 10.1002/pros.23378. View

16.

Kogata Y, Tanaka T, Ono Y, Hayashi M, Terai Y, Ohmichi M . Foretinib (GSK1363089) induces p53-dependent apoptosis in endometrial cancer. Oncotarget. 2018; 9(32):22769-22784. PMC: 5978264. DOI: 10.18632/oncotarget.25232. View

17.

Shah M, Wainberg Z, Catenacci D, Hochster H, Ford J, Kunz P . Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One. 2013; 8(3):e54014. PMC: 3597709. DOI: 10.1371/journal.pone.0054014. View

18.

Naing A, Kurzrock R, Adams L, Kleha J, Laubscher K, Bonate P . A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors. Invest New Drugs. 2010; 30(1):327-34. DOI: 10.1007/s10637-010-9536-x. View